Psychometric validation of the Breast Cancer Treatment Outcome Scale (BCTOS-12): a prospective cohort study

Feißt, Manuel; Heil, Jörg; Stolpner, Ilona; Au, Alexandra von; Domschke, Christoph; Sohn, Christof; Kieser, Meinhard; Rauch, Geraldine; Hennigs, André

doi:10.1007/s00404-019-05362-y

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EORTC QLQ BR23 was partly completed in three studies [ 41 , 54 , 70 ], using only the breast symptoms subscale with or without the arm symptom subscale, which measured symptoms rather than QOL, per se. The BCOTS-22, BCOTS-13 and BCOTS-12 had conflicting reporting of the construct it measured, with some studies reporting the subscales separately and used the subscales as a measure of cosmesis, pain and/or function [ 30 , 38 – 42 , 45 , 46 , 49 , 50 , 66 , 67 , 69 – 71 ], while others combined the subscales to measure QOL [ 47 , 48 , 65 , 68 ].…”

Section: Resultsmentioning

confidence: 99%

Quantification of breast lymphoedema following conservative breast cancer treatment: a systematic review

et al. 2022

View full text Add to dashboard Cite

Purpose Breast lymphoedema is a possible side effect of breast conserving surgery, but it is poorly understood. This is due, in part, to difficulty assessing the breast. This systematic review described outcome measures that quantify breast lymphoedema signs and symptoms and evaluated the measurement properties for these outcome measures. Method Seven databases were searched using terms in four categories: breast cancer, lymphoedema and oedema, clinician reported (ClinROM) and patient reported outcome measures (PROM) and psychometric and measurement properties. Two reviewers independently reviewed studies and completed quality assessments. The Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) methodology was used for studies including measurement property evidence. Results Fifty-six papers were included with thirteen questionnaires, eight patient-reported rating scales, seven physical measures, seven clinician-rating scales and four imaging techniques used to quantify breast lymphoedema. Based on COSMIN methodology, one ClinROM had sufficient reliability, ultrasound measuring dermal thickness. Tissue dielectric constant (TDC) measuring local tissue water had promising reliability. Four questionnaires had sufficient content validity (BLYSS, BLSQ, BrEQ and LYMQOL-Breast). Conclusions Ultrasound is recommended to reliably assess breast lymphoedema signs. No PROM can be recommended with confidence, but BLYSS, BLSQ, BrEQ and LYMQOL-Breast are promising. Further research is recommended to improve evidence of measurement properties for outcome measures. Implications for Cancer Survivors There are many approaches to assess breast lymphoedema, but currently, only ultrasound can be recommended for use, with others, such as TDC and questionnaires, showing promise. Further research is required for all approaches to improve evidence of measurement properties.

show abstract

Section: Resultsmentioning

confidence: 99%

Quantification of breast lymphoedema following conservative breast cancer treatment: a systematic review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…All patients were followed up for 1 year postoperatively for breast satisfaction by two independent investigators. The location, shape, size, and symmetry of the breasts were assessed using the Harris evaluation criteria (23). The satisfaction rate of postoperative breast aesthetics was 90.9% in group A and 89.3% in group B after 1 year, suggesting that there was little difference between two methods.…”

Section: Resultsmentioning

confidence: 99%

Strategies for the selection of oncoplastic techniques in the treatment of early-stage breast cancer patients

Huang¹,

Qiu²,

Li³

et al. 2021

Gland Surg

View full text Add to dashboard Cite

Background: In recent years, breast cancer is the most common malignancy in women. The traditional method of surgery is to remove a woman's breast completely, which has a negative impact on her work and life. Today, women have a fiery pursuit to maintain their perfect figure, which has forced breast surgeon to find a new surgical approach to maintain the shape of the breast after surgery.Methods: This study systematically analyzed and summarized the incision design and repair of glandular defects in early-stage breast cancer patients by oncoplastic breast techniques. By summarizing the methods of oncoplastic breast surgery (OBS) in different quadrants, it could help beginners to master this technology more quickly, so as to provide better help for breast cancer patients.Results: A total of 216 breast cancer patients who underwent OBS from January 2016 to June 2020 at the Affiliated Hospital of Guangdong Medical University were included in this study. In patients treated with the volume-displacement method and the volume-replacement method, 92.6% and 86.2% of patients achieved excellent breast shape, respectively.Conclusions: OBS is a safe and effective way to treat early-stage breast cancer while obtaining better breast shape, reducing postoperative psychological trauma, and improving quality of life.

show abstract

“…Once chemotherapy is completed, patients may focus on their physical appearance and self-perception and, therefore, consider surgical removal of their port system (venous access device) [ 15 ]. While this procedure rarely involves clinical complications, patients still mention unsightly scarring, general discomfort in the surgical area, and occasionally arm pain.…”

Section: Introductionmentioning

confidence: 99%

Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients

Eichler

Üner

Thangarajah

et al. 2022

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose Platelet-rich plasma (PRP) is widely used product, and meta-analyses showed this product to be beneficial when applied to a wound area. This study group has already demonstrated increased patient satisfaction and lower complication rates in breast cancer patients who received PRP after removal of their subcutaneous venous access device. This work is a follow-up analysis focusing on oncologic safety. Currently, there is no long-term data on the use of PRP products in cancer patients available yet. Methods Between the years 2012–2016, venous access device removal was supported with the application of Arthrex ACP® (Autologous Conditioned Plasma)—a PRP product to improve the wound-healing process. All surgeries were performed in the breast cancer center of the municipal hospital of Cologne, Holweide, Germany. 35 patients received an application of Arthrex ACP® after port removal compared to the control group of 54 patients. Endpoints were local recurrence-free, distant recurrence-free as well as overall survival. Results Median follow-up was 45 months. No (0) adverse events were shown for cancer recurrence within the subcutaneous venous access device scar area. Thus, there seems to be no local oncogenic potential of the PRP product. All other endpoints as well as any-cause death numerically favor PRP use. Conclusion PRP products such as Arthrex ACP® seem to be oncological inert when applied after removal of subcutaneous access devices. This is the first study providing long-term data about overall survival, distant recurrence-free and local recurrence-free survival after applying PRP in high-risk cancer patients.

show abstract

Psychometric validation of the Breast Cancer Treatment Outcome Scale (BCTOS-12): a prospective cohort study

Cited by 5 publications

References 36 publications

Quantification of breast lymphoedema following conservative breast cancer treatment: a systematic review

Quantification of breast lymphoedema following conservative breast cancer treatment: a systematic review

Strategies for the selection of oncoplastic techniques in the treatment of early-stage breast cancer patients

Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients

Contact Info

Product

Resources

About